These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38670236)

  • 21. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
    Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
    Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cutaneous ALK rearranged spindle cell neoplasm and S-100/CD34 co-expression: report of a case].
    Zhang W; Wang Y; Wang H; Gao Y; Chen YL
    Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):498-500. PubMed ID: 38678336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALK-rearranged renal cell carcinoma with a novel PLEKHA7-ALK translocation and metanephric adenoma-like morphology.
    Hang JF; Chung HJ; Pan CC
    Virchows Arch; 2020 Jun; 476(6):921-929. PubMed ID: 31993771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases.
    Hodge JC; Pearce KE; Wang X; Wiktor AE; Oliveira AM; Greipp PT
    Mod Pathol; 2014 Jan; 27(1):113-27. PubMed ID: 23828314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next generation sequencing-based identification of fusion-driven renal neoplasia: A single institution experience.
    Tekin B; Hofich CD; Pitel BA; Schoolmeester JK; Whaley RD; Raghunathan A; Ebare K; Stanton ML; Reynolds JP; Sharma V; Thompson RH; Boorjian SA; Leibovich BC; Herrera Hernandez LP; Jimenez RE; Cheville JC; Ketterling RP; Geiersbach KB; Greipp PT; Sukov WR; Kipp BR; Halling KC; Gupta S
    Hum Pathol; 2024 Oct; 152():105542. PubMed ID: 38145826
    [No Abstract]   [Full Text] [Related]  

  • 26. Characteristics of Renal Cell Carcinoma Harboring
    Woo CG; Yun SJ; Son SM; Lim YH; Lee OJ
    Yonsei Med J; 2020 Mar; 61(3):262-266. PubMed ID: 32102128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of ALK-rearranged renal cell carcinomas with a focus on clinical and pathobiological aspects.
    Kuroda N; Sugawara E; Kusano H; Yuba Y; Yorita K; Takeuchi K
    Pol J Pathol; 2018; 69(2):109-113. PubMed ID: 30351856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salivary Secretory Carcinoma Harboring a Novel ALK Fusion: Expanding the Molecular Characterization of Carcinomas Beyond the ETV6 Gene.
    Sasaki E; Masago K; Fujita S; Suzuki H; Hanai N; Hosoda W
    Am J Surg Pathol; 2020 Jul; 44(7):962-969. PubMed ID: 32205481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1.
    Caliò A; Harada S; Brunelli M; Pedron S; Segala D; Portillo SC; Magi-Galluzzi C; Netto GJ; Mackinnon AC; Martignoni G
    Mod Pathol; 2021 Apr; 34(4):842-850. PubMed ID: 33208882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ALK rearrangement in sickle cell trait-associated renal medullary carcinoma.
    Mariño-Enríquez A; Ou WB; Weldon CB; Fletcher JA; Pérez-Atayde AR
    Genes Chromosomes Cancer; 2011 Mar; 50(3):146-53. PubMed ID: 21213368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The translocation carcinoma: A pediatric renal tumor also in adults].
    Bruder E; Moch H
    Pathologe; 2016 Mar; 37(2):159-65. PubMed ID: 26972595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.
    Katayama R
    Cancer Sci; 2018 Mar; 109(3):572-580. PubMed ID: 29336091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel
    Shimizu N; Akashi Y; Fujii T; Shiono H; Yane K; Kitahara T; Ohta Y; Kakudo K; Wakasa T
    Anticancer Res; 2019 Jan; 39(1):413-420. PubMed ID: 30591488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ALK-rearrangement in non-small-cell lung cancer (NSCLC).
    Du X; Shao Y; Qin HF; Tai YH; Gao HJ
    Thorac Cancer; 2018 Apr; 9(4):423-430. PubMed ID: 29488330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted next-generation sequencing revealed distinct clinicopathologic and molecular features of VCL-ALK RCC: A unique case from an older patient without clinical evidence of sickle cell trait.
    Wang XT; Fang R; Ye SB; Zhang RS; Li R; Wang X; Ji RH; Lu ZF; Ma HH; Zhou XJ; Xia QY; Rao Q
    Pathol Res Pract; 2019 Nov; 215(11):152651. PubMed ID: 31563285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR.
    Li Y; Pan Y; Wang R; Sun Y; Hu H; Shen X; Lu Y; Shen L; Zhu X; Chen H
    PLoS One; 2013; 8(7):e69016. PubMed ID: 23922677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Anaplastic lymphoma kinase-translocation renal cell carcinoma: clinical and pathological analysis].
    Di SH; Wang XT; Xia QY; Lu ZF; Ma HH; Zhang RS; Wang X; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2022 Jan; 51(1):28-32. PubMed ID: 34979750
    [No Abstract]   [Full Text] [Related]  

  • 38. NTRK-rearranged spindle cell sarcoma of the uterine cervix with a novel NUMA1::NTRK1 fusion.
    Szalai L; Vereczkey I; Szemes M; Rókusz A; Csernák E; Tóth E; Melegh Z
    Virchows Arch; 2024 Mar; 484(3):527-531. PubMed ID: 38151535
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.
    Kang J; Deng QM; Peng KC; Li P; Zhu BT; Wang P; Chu XP; Zhong WZ; Chen HJ; Wang WX; Chen HF; Rao CZ; Xu CW; Yang JJ
    Genes Chromosomes Cancer; 2022 Apr; 61(4):177-186. PubMed ID: 34687488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.